RxDoctor Payments Data

Elaine Sorem, MD

Psychiatry · Elkhorn, WINPI 1629167085

Payments from drug & device makers

$767in general payments, 2019–2025

Across 29 payments — averaging $26.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$217
  • Neurocrine Biosciences, Inc.$159
  • Johnson & Johnson$153
  • Teva Pharmaceuticals USA, Inc.$70
  • Axsome Therapeutics, Inc.$59
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$49
  • plus $60 from 2 others

What the payments were for

  • Food & beverage$71894%
  • Education$496%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 80th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$7,392
Medicare patients
29
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate58$479,634
Invega SustennaPaliperidone Palmitate27$97,610
Risperdal ConstaRisperidone Microspheres47$43,873
Abilify MaintenaAripiprazole17$38,517
Clozapine OdtClozapine34$11,719
Clozapine147$10,549
VyvanseLisdexamfetamine Dimesylate17$6,472
Aripiprazole79$4,994
Quetiapine Fumarate150$3,427
Lurasidone Hcl21$3,308
Fluoxetine Hcl203$2,510
Paliperidone ErPaliperidone16$2,227
Risperidone156$1,949
Haloperidol41$1,937
Olanzapine OdtOlanzapine24$1,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$159$479,63458 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$153$141,48374 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Elkhorn

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →